Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Autozone Inc (AZO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Autozone Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Autozone Inc trades at $3,042 (market cap $49.67B). The key difference: Autozone Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ALNY | AZO | |
|---|---|---|
Market Cap | $29.60B | $49.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $4.35K |
52-Week Low | $205.48 | $2.92K |
Enterprise Value | $27.56B | $62.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
AutoZone (AZO) trades at $3,045.87, down 0.72% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though recent Q3 2025 EPS missed expectations while Q4 2025 and Q1 2026 beat. Operating cash flow remains robust at $3.12B, supporting ongoing expansion initiatives. Recent organizational changes and international growth strategies highlight management's focus on long-term value creation.
AZO presents a compelling value opportunity with 72.7% analyst buy ratings and $3,730 consensus price target representing 22% upside. Key risks include margin compression trends and competitive pressures in auto parts retail. The stock's current technical weakness contrasts with strong institutional conviction, creating potential for recovery if earnings momentum improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
